anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to compounds of the formula (I):   wherein Ar 1  means heterocyclic group representing pyrazole that can be substituted with one or some radicals R 1 ,R 2  or R 3 ; Ar 2  means phenyl, naphthyl or tetrahydronaphthyl being each of them is substituted optionally with one-three groups R 2 ; L means saturated or unsaturated branched or linear carbon C 1 -C 10 -chain wherein one or some methylene groups are replaced optionally with oxygen atom, NH or sulfur atom and wherein a binding group is substituted optionally with 0-2 oxo-groups; Q has values taken among the order: (a) phenyl, naphthyl, pyridine, imidazole, pyrane and so on; (b) tetrahydropyrane, morpholine, thiomorpholine, thiomorpholine sulfoxide and so on; (c) secondary or tertiary amino-group wherein nitrogen atom of amino-group is bound covalently with groups taken among C 1 -C 3 -alkyl, and C 1 -C 5 -alkoxyalkyl; R 1  has values taken among the row: (a) branched or linear C 3 -C 10 -alkyl and so on; (b) C 3 -C 7 -cycloalkyl and so on, or tetrahydropyrane group; R 2  represents branched or linear C 1 -C 6 -alkyl that can be halogenated partially or completely; R 3  is taken among the row including: (a) phenyl, naphthyl and heterocyclic group representing pyridinyl and so on; (b) branched or linear (C 1 -C 6 )-alkyl that can be halogenated partially or completely and that can be substituted with phenyl group; R 4  and R 5  mean morpholine; X means oxygen atom; and to their physiologically acceptable salts and acids. Invention proposes method for preparing compounds of the formula (I). Also, invention proposes pharmaceutical composition inhibiting producing cytokines comprising compound by cl. 1 or its pharmaceutically acceptable derivatives as an active substance and usual adjuvants. Invention proposes methods for treatment of inflammatory and autoimmune disease that involve administration to patient needing treatment compound by cl. 1 taken in therapeutically effective amount. Invention provides preparing aromatic heterocyclic compounds as anti- -inflammatory agents. EFFECT: valuable medicinal properties of compounds. 17 cl, 16 sch, 3 tbl, 57 ex
OBJECTIVE: Early identification of complicated acute diverticulitis(cAD) is especially significant for clinical physician and surgeon to reduce the antibiotic usage and the risk of emergency surgery. This study was aimed to investigate the significance of immature granulocyte(IG) count in early prediction for right-side(Rt-side) cAD.
METHODS: The patients with Rt-side colonic acute diverticulitis was enrolled between January, 2019 and March, 2024, and divided into complicated and simple acute diverticulitis group(cAD and sAD). The data about demographic, clinical and laboratory parameters were collected and compared. Logistic regression analysis and receiver operator characteristic(ROC) curves were used to assess the predictive values of these parameters for Rt-side complicated diverticulitis.
RESULTS: 289 participants who met the inclusion criteria were followed as 31 patients in cAD group and 258 in sAD group. Compared to sAD group, cAD group had the higher body mass index(BMI) and peripheral blood routine parameters, especially IG count, systemic immune inflammation index(SII) and neutrophil-to-lymphocyte ratio(NLR), with the statistically significant differences(P<0.001). Moreover, logistic regression analysis indicated that IG count was a significant and independent predictors for cAD(OR 4.92, 95%CI 3.86-8.39). In the ROC analysis, area under the ROC curves (AUC) was found for IG count(0.93(95%CI 0.88-0.99) ) and SII(0.88(95%CI 0.820-0.95)). The optimal cut-off value of IG count was 0.10 with the largest sensitivity of 80.60% and specificity of 100.00% for identifying Rt-side colonic complicated diverticulitis.
CONCLUSION: IG count was a more comparable and independent predictor for Rt-side colonic complicated diverticulitis with a largest AUC than other markers in complete blood count (CBC). Given its early arise, easy accessibility and no-radiation, it can largely convince physicians' decision-making of antibiotic abuse and surgeons' early intervention in Rt-side colonic cAD.
Soccer is one of the most popular sports worldwide, played by over 270 million people and followed by many more. Several brain health benefits are promoted by practising soccer and physical exercise at large, which helps contrast the cognitive decline associated with ageing by enhancing neurogenesis processes. However, sport-related concussions have been increasingly recognised as a pressing public health concern, not only due to their acute impact but also, more importantly, due to mounting evidence indicating an elevated risk for the development of neurological sequelae following recurrent head traumas, especially chronic traumatic encephalopathy (CTE). While soccer players experience less frequent concussions compared with other contact or combat sports, such as American football or boxing, it stands alone in its purposeful use of the head to hit the ball (headings), setting its players apart as the only athletes exposed to intentional, sub-concussive head impacts. Additionally, an association between soccer and amyotrophic lateral sclerosis has been consistently observed, suggesting a potential "soccer-specific" risk factor. In this review, we discuss the neurological sequelae related to soccer playing, the emerging evidence of a detrimental effect related to recurrent headings, and the need for implementation of comprehensive strategies aimed at preventing and managing the burden of head impact in soccer.
The present invention relates to an improved process of conjugation to obtain synthetic oligosaccharide - protein (OS-PR) conjugates. The process of synthetic OS-PR conjugation is a rapid process providing oligosaccharide - protein conjugates which are highly immunogenic and elicit specific and homogenous immune responses. The synthetic oligosaccharide comprising of four to eight repeating units of respective monomers and at least one in-built terminal amino linker, said synthetic polysaccharide mimics natural polysaccharide obtained from gram negative bacteria such as Neisseria meningitidis serogroups A, C, Y, W, X and Haemophilus influenzae and carrier protein is obtained from gram positive bacteria such as Clostridium tetani (tetanus toxoid) or Corynebacterium diphtheriae (CRM197) or their recombinant versions. The conjugation chemistry of the said oligosaccharide-protein conjugate of the present invention is thio-ether linkage. The present invention takes complete process time in the range of 14-22 hours. The said oligosaccharide-protein conjugates are useful in production of monovalent vaccine or multivalent combination vaccines and as diagnostic tool.
Systems and methods are described for agent-based simulation of each individual's movements in order to monitor the propagation of a disease. An agent-based simulation model has been exemplarily constructed, which is mainly comprised of two parts: student mobility model and disease propagation model. In the student mobility model, movements of students are modeled based on the GIS map (viz. routes, distances) and their daily schedules (e.g. dorms and classrooms/buildings). The disease propagation model represents students' health status (viz. susceptible, pre-symptomatic, asymptomatic, quarantine, isolation, and recovered) based on different factors such as the number of infected students attending the class or living in a dorm, classroom/dorm features (e.g. size, humidity, ventilation), probabilities of disease transmissions (e.g. droplet, airborne) in classrooms based on a dose-response model, probabilities of disease transmissions in dorms based on cohort studies, and mask wearing condition and effectiveness.
Digoxin will be administered orally at a standard maintenance dosing. Each cycle will be 28 days.
Although the role of gut microbiota (GMB)-derived metabolites in mitochondrial and endolysosomal dysfunction in Alzheimer's disease (AD) under metabolic syndrome remains unclear, deciphering these host-metabolite interactions represents a major public health challenge. Dysfunction of mitochondria and endolysosomal networks (ELNs) plays a crucial role in metabolic syndrome and can exacerbate AD progression, highlighting the need to study their reciprocal regulation for a better understanding of how AD is linked to metabolic syndrome. Concurrently, metabolic disorders are associated with alterations in the composition of the GMB. Recent evidence suggests that changes in the composition of the GMB and its metabolites may be involved in AD pathology. This review highlights the mechanisms of metabolic syndrome-mediated AD development, focusing on the interconnected roles of mitochondrial dysfunction, ELN abnormalities, and changes in the GMB and its metabolites. We also discuss the pathophysiological role of GMB-derived metabolites, including amino acids, fatty acids, other metabolites, and extracellular vesicles, in mediating their effects on mitochondrial and ELN dysfunction. Finally, this review proposes therapeutic strategies for AD by directly modulating mitochondrial and ELN functions through targeting GMB metabolites under metabolic syndrome.
Provided is a customized sarcopenia diagnosing and preventing system. The system comprises: a communicating module; a memory; and a processor. The communicating module transmits and receives data with a smart dumbbell device which measures grasping power of a user; a smart health band device which measures a walking speed of the user; a smart muscle band device which measures an electromyogram value and a strain value of the user; and a smart scale which measures a skeletal muscle mass of the user. The memory stores a program for diagnosing and prescribing sarcopenia of the user based on the data. The processor determines whether at least one of the measured grasping power and walking speed of the user is equal to or less than a set first reference value and a set second reference value by executing the program stored in the memory, compares the skeletal muscle mass received through the smart scale with a predetermined third reference value when at least one of the measured grasping power and walking speed of the user is equal to or less than the reference value depending on a determination result, and judges as the sarcopenia when the skeletal muscle mass is less than or equal to the third reference value. The present invention can provide an economic healthcare cost reducing effect.
In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
Disclosed herein is a system for facilitating the management of healthcare delivery processes, in accordance with some embodiments. Accordingly, the system may include a communication device configured for receiving at least one personal medical data from at least one personal device. Further, the communication device may be configured for transmitting at least one notification to at least one of a healthcare provider device of at least one healthcare provider device and a personal device of the at least one personal device. Further, the system may include a processing device configured for analyzing the at least one personal medical data. Further, the processing device may be configured for managing at least one healthcare delivery process based on the analyzing. Further, the system may include a storage device configured for storing the at least one notification and the at least one personal medical data in a database.
INTRODUCTION: prostatitis is defined as a clinical condition caused by acute or chronic infectious diseases, chronic pelvic pain syndrome, or asymptomatic inflammation of the prostate gland. We conducted a study to determine the prevalence of histological prostatitis in patients with prostatic diseases at Potchefstroom Hospital.
METHODS: we conducted a cross-sectional study based on the review of histology report from 1st January 2015 to 31st December 2019 coupled to clinical information of patients. A total of 362 cases with complete histopathology report were included in the study. Chi-square and Fisher exact test were used to test statistical significance with a p-value of 0.05 deemed to be significant.
RESULTS: over a total number of 362 patients, the mean age was 69.82±7.9 years. The overall prevalence of prostatitis on histology was 158 (43.65%). Chronic prostatitis was predominant and commonly associated with BPH or PCa in 142 cases (39.23%) on histopathology report, while acute prostatitis was found in 16 patients (4.42%). We further found prostate cancer in 178 patients (49.17%), BPH in 163 (45.03%). The study shows that 41 cases (23.3%) of prostate cancer were associated with prostatitis, and 96 cases (58.9%) of BPH were also associated with prostatitis on histology. The difference was statistically significant p < 0.001. The study revealed that in BPH with prostatitis the median PSA was 15 ng/ml (IQR 9-24), while in BPH without prostatitis the median PSA was 11ng/ml (IQR 7-16). (p < 0.017). This means that prostatitis increases PSA in patients with BPH. However, the presence of prostatitis did not significantly influence the PSA value in patients with prostate cancer.
CONCLUSION: this study showed that close to half of the histology examined had signs of prostatitis. Chronic prostatitis was more frequent on histology done in our sample. BPH was strongly associated with prostatitis. Prostatitis contributed to a higher PSA values in patients with BPH and did not influence the PSA value in PCa.
The invention relates to medicinal bait used for controlling juvenile fish diseases. The medicinal bait is composed of medicinal bait I and medicinal bait II which are prepared with a common feedstuff as a main material. The medicinal bait I and the medicinal bait II are alternatively applied in different time periods. The medicinal bait I comprises the common feedstuff, povidone iodine, common andrographis herb, and indigowoad root. The medicinal bait II comprises the common feedstuff and moroxydine. In the medicinal bait I, every kilogram of the common feedstuff is mixed with 1-2ml of povidone iodine and 10-20g of povidone iodine and indigowoad root. In the medicinal bait II, every kilogram of the common feedstuff is mixed with 0.1-0.4g of moroxydine. With the medicinal bait provided by the invention, the fish disease is mainly treated by using Chinese herbal medicines. Therefore, the medicinal bait is green and environment-friendly. The medicinal bait causes low toxic and side effect, and low residue. With the medicinal bait, physiological functions of fish can be comprehensively regulated, such that nutritional and medical dual effects are provided. The application effect of the medicinal bait is good. With the medicinal bait, the spreading of juvenile fish disease syndromes can be effectively controlled, and sick fish can be rapidly cured.
The attention deficit hyperactivity disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 1,000 patients with depressive disorders.
PURPOSE:To obtain a composition for oral cavity application exhibiting excellent effect to prevent the formation of bacterial plaque and dental caries by compounding cetyl pyridinium chloride and an N<alpha>-long-chain acyl basic amino acid lower alkyl ester. CONSTITUTION:The objective composition can be produced by compounding >=0.0002wt.% and usually <=1wt.% of cetyl pyridinium chloride and >=1/5 pts.wt., usually 1/5 to 10 pts.wt. (based on 1 pt. wt. of the cetyl pyridinium chloride) of an N<alpha>-long-chain acyl basic amino acid lower alkyl ester, mixing with desired components by conventional method and forming in the form of a drug. It can be used as tooth powder, tooth paste, gargle or troche or sprayed into oral cavity as aerosol. It can also be used as a tooth-application agent by impregnating in a dental floss or a toothpick. The adsorption of the antibacterial cetyl pyridinium chloride to the surface of tooth can be promoted by this process.
Participants in the control group will receive the usual psychosocial care provided by the staff nurses. To offer them attention, a research assistant in each hospital will meet them every week for 30 minutes to ask them about treatment adherence and any other concerns. The parents will be invited to attend it if they want to do so. Each participant will be given an appointment slip and reminded with a phone call two days before the next appointment. For participants whose medical appointment is more than a week, the research will contact them via phone.
Platinum deplatinization has been extensively explored in patients with posterior nasopharyngeal carcinoma who have received multiple platinum treatments, including target-free combination, GEP, etc. Our center also published in 2022 CSCO a study on the preliminary efficacy of pembrolizumab combined with gemcitabine in the first-line treatment of metastatic NPC with or without cisplatin or anlotinib. Enrolled patients were treated with pembrolizumab + anlotinib +GP (group A), pembrolizumab +GP (group B), and pembrolizumab + anlotinib +G (group C), with ORR of 80% (4/5), 80% (4/5), and 100% (7/7), respectively. Among them, there were 1 CR and 6 PR in group C. Compared to group B, group C with anlotinib in place of cisplatin showed a better safety profile with fewer grade 3 adverse reactions (57.1% vs 100%). In summary, we designed this study to evaluate the efficacy and safety of gemcitabine, sintilimab and bevacizumab combined with IMRT in patients with advanced nasopharyngeal carcinoma not suitable for platinum-based treatment, and to explore new therapeutic approaches for patients with advanced stage nasopharyngeal carcinoma who cannot tolerate platinum therapy or are unwilling to receive platinum therapy.

This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
The inhibitor-kappaB kinase epsilon (IKKε) represents a non-canonical IκB kinase that modulates NF-κB activity and interferon I responses. Inhibition of this pathway has been linked with atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD), yet the results are contradictory. In this study, we employed a combined model of hepatic PCSK9D377Y overexpression and a high-fat diet for 16 weeks to induce atherosclerosis and liver steatosis. The development of atherosclerotic plaques, serum lipid concentrations, and lipid metabolism in the liver and adipose tissue were compared between wild-type and IKKε knock-out mice. The formation and progression of plaques were markedly reduced in IKKε knockout mice, accompanied by reduced serum cholesterol levels, fat deposition, and macrophage infiltration within the plaque. Additionally, the development of a fatty liver was diminished in these mice, which may be attributed to decreased levels of multiple lipid species, particularly monounsaturated fatty acids, triglycerides, and ceramides in the serum. The modulation of several proteins within the liver and adipose tissue suggests that de novo lipogenesis and the inflammatory response are suppressed as a consequence of IKKε inhibition. In conclusion, our data suggest that the knockout of IKKε is involved in mechanisms of both atherosclerosis and MASLD. Inhibition of this pathway may therefore represent a novel approach to the treatment of cardiovascular and metabolic diseases.
Participants received two SC injections of Placebo as a loading dose at Baseline in combination with topical corticosteroid and Week 2 followed by a single injection Q2W from Week 4 until Week 14. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
FIELD: medicine, surgery. SUBSTANCE: the area of anastomosis sutures should be protected with a film explant prepared out of modified hyaluronic acid. Moreover, a part of carboxylic groups of hyaluronic acid is covalently connected with 5- aminosalicylic acid. The method enables to stimulate tissue regeneration in anastomosis area. This favors to prevent possible failure of anastomosis sutures. EFFECT: higher efficiency of protection. 1 ex, 1 tbl
Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m\^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
Multiple myeloma (MM) is a plasma cell malignancy that resides within the bone marrow microenvironment, relying heavily on interactions with its cellular components. Among these, endothelial cells (ECs) play a pivotal role in MM progression and the development of therapeutic resistance. In this study, we analyzed publicly available single-cell RNA sequencing data to identify unique pathway activations distinguishing ECs from MM patients and healthy donors. We developed a novel protocol to isolate and culture endothelial progenitor cells (EPCs) and ECs directly from MM patient bone marrow, demonstrating their ability to promote myeloma cell proliferation. Validation studies confirmed that these MM-derived ECs exhibit angiogenic potential as well as the expression of characteristic endothelial lineage markers. These findings underscore the critical role of bone marrow ECs in the MM tumor microenvironment and highlight potential new therapeutic targets to disrupt MM progression.